Syndexa Pharmaceuticals Adds to B1 Round
Watertown, Mass.-based Syndexa Pharmaceuticals Corp. has raised an undisclosed amount of Series B1 financing from MP Healthcare Venture Management. Total capital raised in the B1 round was $8.5 million. Syndexa is developing drugs to treat metabolic diseases.
Bycnolan
5 January 2012•2 mins read
